@dansfera: Small-cap biotech investing is all about the waiting game. For those tracking companies like Iova, Equillium, or Atai, every date circled on the calendar represents a massive catalyst. Clinical trial results—whether interim or top-line data—are the ultimate drivers of volatility and potential growth in this sector. Understanding the timing of these updates is key to navigating the high-stakes world of biotech portfolios. #biotechstocks #investingtips #stockmarket #smallcapstocks #clinicaltrials